SCHEMBL4080996

SCHEMBL4080996

CCN1CCC(NC(=O)c2ccc(Nc3ncc4c(n3)N(C3CCCC3)CC(C)C(=O)N4C)cc2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 9/20 0.66
TAF1 P21675 3/20 0.66
PLK1 P53350 14/20 0.62
ALK Q9UM73 3/20 0.53
BRDT Q58F21 5/20 0.52
PLK3 Q9H4B4 6/20 0.51
PLK2 Q9NYY3 4/20 0.51
DAPK3 O43293 2/20 0.51
PRKD3 O94806 2/20 0.51
CHEK2 O96017 2/20 0.51
EGFR P00533 2/20 0.51
FES P07332 2/20 0.51
PHKG2 P15735 2/20 0.51
CSNK1D P48730 2/20 0.51
CLK2 P49760 2/20 0.51
NEK2 P51955 2/20 0.51
PTK2 Q05397 2/20 0.51
CAMK2B Q13554 2/20 0.51
CAMK2G Q13555 2/20 0.51
CAMK2D Q13557 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4080359 0.92 BRD4 (0.77) BRD4TAF1PLK1ALKBRDT
SCHEMBL4075904 0.92 BRD4 (0.55) BRD4TAF1PLK1ALKBRDT
SCHEMBL4078301 0.89 PLK1 (0.67) BRD4TAF1PLK1ALKBRDT
SCHEMBL3667459 0.89 PLK1 (0.55) BRD4TAF1PLK1ALKBRDT
SCHEMBL1560017 0.84 PLK1 (0.85) BRD4TAF1PLK1ALKBRDT
SCHEMBL4081000 0.84 BRD4 (0.65) BRD4TAF1PLK1ALKBRDT
SCHEMBL4079129 0.84 PLK1 (0.57) BRD4TAF1PLK1BRDTPLK3
SCHEMBL3672321 0.83 PLK1 (0.58) BRD4TAF1PLK1ALKBRDT
SCHEMBL4079275 0.82 BRD4 (0.54) BRD4TAF1PLK1BRDTPLK3
SCHEMBL4085018 0.82 PLK1 (0.55) BRD4TAF1PLK1BRDTPLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7517873-B2 Substituted pyrimidodiazepines HOFFMAN-LA ROCHE INC. (US) 2009-04-14 US disclosed
US-7517873-B2 Substituted pyrimidodiazepines HOFFMAN-LA ROCHE INC. (US) 2009-04-14 US disclosed
US-7517873-B2 Substituted pyrimidodiazepines HOFFMAN-LA ROCHE INC. (US) 2009-04-14 US disclosed
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-25 US disclosed
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-25 US disclosed
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES PLK1, CCNI, CDK1 BRD4 123/4885TAF1 3573/4885PLK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.